I'm with you there.That's good, I'd trust INIM with that but personally I would not trust Quest to do the same.
True, but OMI and INIM also focus on pathogen testing and treatment. In additon, they look at immune dysfunction and treat where there is some possibliity of doing so. IVIG for low IgG, Imunovir or inosine for low NK cell function, and so on. I can spend longer off AVs when I get some immune treatment, which is easier on my liver and kidneys.Their main focus appears to be pathogen testing and treatment, so it wouldn't change their treatment plan if you had low or normal NK cell function. They would give antivirals/abx regardless and that is their main approach.
Not all groups test and treat the same since there's no established protocol yet, but since the direction of research is definitely suggesting immune implications in this neuroimmune illness, I'm surprised a university clinic isn't looking as the immune side. Oh well, the top folks are doing the best they can in the environment they're in. We can't fairly ask for more.
Me, too. We need to know a lot more about the progression of this illness. It's clear a lot of things are changing significantly over time.I really wish that all new ME research would take into account duration of illness in their cohort.
Oddly, my NK cell function and cytokines look like those of a young short-term patient rather than the old, long-term patient that I am. I wonder if that has anything to do with getting a lot of pathogen and immune treatments. Perhaps my immune system is getting enough support from those treatments that it's no longer exhausted and is back in fight mode.